Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.46 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL245866 | 0.86 | KDM4E (0.50) | KDM4EALDH1A1MAPTHSD17B10MEN1 | |
| SCHEMBL30511861 | 0.85 | PRF1 (0.58) | KDM4EALDH1A1MAPTHSD17B10MEN1 | |
| SCHEMBL245940 | 0.85 | PRF1 (0.58) | KDM4EALDH1A1MAPTHSD17B10MEN1 | |
| SCHEMBL3338306 | 0.84 | ADORA1 (0.60) | KDM4EALDH1A1MAPTHSD17B10MEN1 | |
| SCHEMBL245484 | 0.82 | KDM4E (0.48) | KDM4EALDH1A1MAPTHSD17B10MEN1 | |
| SCHEMBL13929770 | 0.82 | KDM4E (0.52) | KDM4EALDH1A1MAPTHSD17B10MEN1 | |
| SCHEMBL3359383 | 0.80 | KDM4E (0.60) | KDM4EALDH1A1MAPTHSD17B10MEN1 | |
| SCHEMBL245311 | 0.80 | ADORA1 (0.48) | KDM4EALDH1A1MAPTHSD17B10MEN1 | |
| SCHEMBL14040006 | 0.80 | KDM4E (0.45) | KDM4EALDH1A1MAPTHSD17B10MEN1 | |
| SCHEMBL25365985 | 0.79 | ADORA1 (0.55) | KDM4EALDH1A1MAPTHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691850-B2 | Substituted phenylaminothiazoles and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-08 | — | — | US | disclosed |
| US-20100048641-A1 | Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases | BAYER HEALTHCARE AG LAW AND PATENTS,PATENTS AND LICENSING (DE) | 2010-02-25 | — | — | US | disclosed |
| EP-1812430-B1 | SUBSTITUTED PHENYLAMINOTHIAZOLES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2009-04-15 | — | — | EP | disclosed |
| EP-1812430-B1 | SUBSTITUTED PHENYLAMINOTHIAZOLES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2009-04-15 | — | — | EP | disclosed |
| EP-1994031-A1 | USE OF ADENOSINE A1 AND/OR DUAL A1/A2B AGONISTS FOR PRODUCTION OF MEDICAMENTS FOR TREATING DISEASES | Bayer HealthCare AG (DE) | 2008-11-26 | — | — | EP | disclosed |
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| WO-2007101531-A1 | USE OF ADENOSINE A1 AND/OR DUAL A1/A2B AGONISTS FOR PRODUCTION OF MEDICAMENTS FOR TREATING DISEASES | BAYER HEALTHCARE AG (DE) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007101531-A1 | USE OF ADENOSINE A1 AND/OR DUAL A1/A2B AGONISTS FOR PRODUCTION OF MEDICAMENTS FOR TREATING DISEASES | BAYER HEALTHCARE AG (DE) | 2007-09-13 | — | — | WO | disclosed |
| EP-1812430-A1 | SUBSTITUTED PHENYLAMINOTHIAZOLES AND USE THEREOF | Bayer HealthCare AG (DE) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006027142-A1 | SUBSTITUTED PHENYLAMINOTHIAZOLES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048641-A1 | Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases | ADORA1, ADORA2B, ADORA2A | KDM4E 4410/4885ALDH1A1 312/4885MAPT 4545/4885 |
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | PAH, TNNT2, VHL | KDM4E 1932/4885ALDH1A1 739/4885MAPT 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.